Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy

International Journal of Impotence Research volume 20, pages 561–565 (2008)Cite this article

Abstract

The primary objective of this study was to correlate simultaneous measures of prostate-specific antigen (PSA) and serum testosterone among large samples of eugonadal, untreated hypogonadal and hypogonadal men treated with testosterone replacement therapy (TRT). From 2001 to 2007, laboratory records were reviewed to identify men who underwent simultaneous measurement of PSA and serum testosterone levels. The data were stratified based on three groups of men: group 1 consisted of eugonadal men (T>300 ng per 100 ml) evaluated for BPH, reproductive failure or sexual dysfunction; group 2 consisted of untreated hypogonadal men (T<300 ng per 100 ml); and group 3 comprised symptomatic hypogonadal men receiving TRT. Correlations were found between PSA (total and free fractions) and total serum testosterone levels among the three groups. Group 1: eugonadal men (n=385 patients), mean PSA and serum testosterone were 1.60 ng ml−1 and 484 ng 100 ml, respectively. There was no significant correlation between PSA and total serum testosterone levels (r=−0.01, P=0.8). Group 2: untreated hypogonadal men (n=229 patients), mean PSA and serum testosterone were 1.49 ng ml−1 and 269 ng per 100 ml, respectively. There was no significant correlation between PSA and total serum testosterone levels (r=0.03, P=0.6). Group 3: hypogonadal men on TRT (n=229 patients and 994 individual samples analyzed) mean PSA and serum testosterone were 1.50 ng ml−1 and 555 ng per 100 ml, respectively. There was no significant correlation between PSA and serum testosterone levels (r=−0.005, P=0.9). Mean total serum testosterone levels were increased significantly (P<0.001) following treatment. Mean PSA levels did not increase in a statistically or clinically significant manner following TRT (mean PSA increase from baseline 0.05 ng ml−1, P=0.6). In conclusion, TRT does not appear to significantly influence serum PSA expression and no significant correlation was identified between PSA and serum testosterone among eugonadal, untreated hypogonadal and hypogonadal men receiving TRT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Huggins C, Hodges CV . The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic cancer of the prostate. Cancer Res 1941; 293–297.

  2. Fowler Jr JE, Whitmore Jr WF . The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126: 372–375.

    Article  PubMed  Google Scholar 

  3. Prout GR, Brewer WR . Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967; 20: 1871–1878.

    Article  PubMed  Google Scholar 

  4. Rhoden EL, Morgentaler A . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492.

    Article  CAS  PubMed  Google Scholar 

  5. Rhoden EL, Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170: 2348–2351.

    Article  CAS  PubMed  Google Scholar 

  6. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351–2361.

    Article  CAS  PubMed  Google Scholar 

  7. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. Testosterone therapy in adult men with androgen deficiency syndromes: endocrine society clinical practice guidelines. J Clin Endocrinol Metab 2006; 91: 1995–2010; http://www.endo-society.org/publications/guidelines/final/upload/AndrogensMenGuideline053006.pdf

    Article  CAS  PubMed  Google Scholar 

  8. Canadian Society for the Study of the Aging Male (CSSAM), www.canadianguidelines.com/PDF/01_Andropause.pdf.

  9. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255–260.

    Article  CAS  PubMed  Google Scholar 

  10. Beaulac JA, Fry RN, Onysko J . Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006; 97: 171–176.

    PubMed  PubMed Central  Google Scholar 

  11. Monath JR, McCullough DL, Hart LJ, Jarow JP . Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology 1995; 46: 58–61.

    Article  CAS  PubMed  Google Scholar 

  12. Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB . Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001; 57: 930–935.

    Article  CAS  PubMed  Google Scholar 

  13. Endogenous Hormones, Prostate Cancer Collaborative Group Roddam AW ## Allen NE ## Appleby P, Key TJ . Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170–183.

    Article  Google Scholar 

  14. Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int 2008; 80: 134–140. E-pub 2008 March 19.

    Article  CAS  PubMed  Google Scholar 

  15. Rhoden EL, Riedner CE, Morgentaler A . The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008; 179: 1741–1744.

    Article  CAS  PubMed  Google Scholar 

  16. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren III R, Murphy GP . Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol 1995; 59: 246–250.

    Article  CAS  PubMed  Google Scholar 

  17. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD . Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922–926.

    PubMed  Google Scholar 

  18. Rhoden EL, Morgentaler A . Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006; 18: 201–205.

    Article  CAS  PubMed  Google Scholar 

  19. Saad F, Gooren L, Haider A, Yassin A . An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl 2007; 53: 353–357.

    Article  CAS  PubMed  Google Scholar 

  20. Morgentaler A . Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50: 935–939.

    Article  CAS  PubMed  Google Scholar 

  21. Stone NN, Clejan SJ . Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Androl 1991; 12: 376–380.

    CAS  PubMed  Google Scholar 

  22. Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 2006; 66: 439–444.

    Article  CAS  PubMed  Google Scholar 

  23. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K . Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839–844.

    Article  CAS  PubMed  Google Scholar 

  24. Akyol F, Ozyigit G, Selek U, Karabulut E . PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol 2005; 48: 40–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the following potential conflicts of interest: Dr Ethan D Grober: Auxilium—speaker; Solvay—speaker, advisory board. Dr Mohit Khera: Auxilium—speaker, investigator; Solvay—investigator. Dr Larry I Lipshultz: Auxilium—advisory board, investigator, speaker; Solvay—speaker.

Author information

Authors and Affiliations

  1. Division of Urology, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada

    E D Grober

  2. The Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA

    D J Lamb, M Khera, L Murthy & L I Lipshultz

Authors
  1. E D Grober
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D J Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Khera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L I Lipshultz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E D Grober.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grober, E., Lamb, D., Khera, M. et al. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Int J Impot Res 20, 561–565 (2008). https://doi.org/10.1038/ijir.2008.40

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2008.40

Keywords

This article is cited by

Search

Advanced search

Quick links